{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:46:06Z","timestamp":1786977966988,"version":"build-2736575974"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T00:00:00Z","timestamp":1608595200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatol. Commun."],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:p>\n                    Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease with no approved treatments. C\u2010C chemokine receptor types 2 and 5 (CCR2\/CCR5) play an important role in inflammation and fibrosis and are potential therapeutic targets for PSC. We evaluated the efficacy and safety of cenicriviroc (CVC), a dual antagonist of CCR2 and CCR5, for the treatment of PSC. This was a single\u2010arm, open\u2010label, exploratory study of CVC in adults with a clinical diagnosis of PSC, serum alkaline phosphatase (ALP) \u22651.5 times the upper limit of normal (ULN), with or without inflammatory bowel disease, across eight sites in the United States and Canada. The primary endpoint was percent change in ALP over 24 weeks; key secondary efficacy endpoints were proportion of participants who achieved ALP normalization and overall response (decrease to &lt;1.5 times the ULN or 50% decrease). Of the 24 participants, 20 completed the study. The mean age was 43 years, 50% were female, and the mean body mass index was 25 kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    . From a median ALP baseline of 369 U\/L (range: 173, 1,377 U\/L), a median absolute reduction of 49.5 U\/L (range: \u2212460, 416 U\/L) was achieved at week 24, corresponding to a median reduction of 18.0% (range: \u221246%, 89%). No participant achieved ALP normalization or a 50% decrease; 2 participants (10%) achieved a reduction in ALP to &lt; 1.5 times the ULN, and 4 had \u226525% increase. Twenty participants (83.3%) reported at least one adverse event; most were mild to moderate in severity. The most frequent events were rash, fatigue, and dizziness.\n                    <jats:italic toggle=\"yes\">Conclusion:<\/jats:italic>\n                    After 24 weeks of CVC treatment, adults with PSC achieved a modest reduction (median 18%) in the surrogate endpoint of ALP. CVC was well tolerated, and no new safety signals were observed. ClinicalTrials.gov identifier: NCT02653625.\n                  <\/jats:p>","DOI":"10.1002\/hep4.1619","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T19:26:48Z","timestamp":1608665208000},"page":"478-490","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":45,"title":["Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study"],"prefix":"10.1097","volume":"5","author":[{"given":"Bertus","family":"Eksteen","sequence":"first","affiliation":[{"name":"Aspen Woods Clinic,Calgary PSC Clinic,Calgary,AB,Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"Bowlus","sequence":"additional","affiliation":[{"name":"Davis School of Medicine,University of California,Sacramento,CA,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2511-7980","authenticated-orcid":false,"given":"Aldo J.","family":"Montano\u2010Loza","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Liver Unit,University of Alberta,Edmonton,AB,Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lefebvre","sequence":"additional","affiliation":[{"name":"Allergan plc,South San Francisco,CA,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Fischer","sequence":"additional","affiliation":[{"name":"Allergan plc,South San Francisco,CA,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Vig","sequence":"additional","affiliation":[{"name":"Allergan plc,South San Francisco,CA,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Bruno","family":"Martins","sequence":"additional","affiliation":[{"name":"Allergan plc,South San Francisco,CA,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawad","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Division of Liver Diseases,Icahn School of Medicine at Mount Sinai,New York,NY,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kidist K.","family":"Yimam","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Liver Transplantation,California Pacific Medical Center,San Francisco,CA,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Pockros","sequence":"additional","affiliation":[{"name":"Scripps Clinic and Scripps Translational Science Institute,La Jolla,CA,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan J.","family":"Feld","sequence":"additional","affiliation":[{"name":"Toronto Center for Liver Disease,Toronto General Hospital,University of Toronto,Toronto,ON,Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2687-940X","authenticated-orcid":false,"given":"Gerald","family":"Minuk","sequence":"additional","affiliation":[{"name":"John Buhler Research Center,University of Manitoba,Winnipeg,MB,Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Levy","sequence":"additional","affiliation":[{"name":"Schiff Center for Liver Diseases,University of Miami,Miami,FL,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,12,22]]},"reference":[{"key":"hep41619-bib-0001-20241015","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/MOG.0b013e3282f9e239","article-title":"An update on primary sclerosing cholangitis","volume":"24","year":"2008","journal-title":"Curr Opin Gastroenterol"},{"key":"hep41619-bib-0002-20241015","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.gastro.2003.07.011","article-title":"Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community","volume":"125","year":"2003","journal-title":"Gastroenterology"},{"key":"hep41619-bib-0003-20241015","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/hep.26565","article-title":"Population\u2010based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis","volume":"58","year":"2013","journal-title":"Hepatology"},{"key":"hep41619-bib-0004-20241015","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/hep.24247","article-title":"Incidence of primary sclerosing cholangitis: a systematic review and meta\u2010analysis","volume":"53","year":"2011","journal-title":"Hepatology"},{"key":"hep41619-bib-0005-20241015","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/j.1572-0241.2007.01103.x","article-title":"The burden of large and small duct primary sclerosing cholangitis in adults and children: a population\u2010based analysis","volume":"102","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"hep41619-bib-0006-20241015","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.23294","article-title":"Diagnosis and management of primary sclerosing cholangitis","volume":"51","year":"2010","journal-title":"Hepatology"},{"key":"hep41619-bib-0007-20241015","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/j.gastro.2013.06.052","article-title":"Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management","volume":"145","year":"2013","journal-title":"Gastroenterology"},{"key":"hep41619-bib-0008-20241015","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0168-8278(01)00288-4","article-title":"Hepatic and extrahepatic malignancies in primary sclerosing cholangitis","volume":"36","year":"2002","journal-title":"J Hepatol"},{"key":"hep41619-bib-0009-20241015","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(13)60096-3","article-title":"Primary sclerosing cholangitis","volume":"382","year":"2013","journal-title":"Lancet"},{"key":"hep41619-bib-0010-20241015","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1053\/j.gastro.2011.06.052","article-title":"Loss of CFTR affects biliary epithelium innate immunity and causes TLR4\u2010NF\u2010\u03baB\u2010mediated inflammatory response in mice","volume":"141","year":"2011","journal-title":"Gastroenterology"},{"key":"hep41619-bib-0011-20241015","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1053\/gast.2001.25516","article-title":"Proinflammatory cytokines inhibit secretion in rat bile duct epithelium","volume":"121","year":"2001","journal-title":"Gastroenterology"},{"key":"hep41619-bib-0012-20241015","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.cgh.2012.12.032","article-title":"Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis","volume":"11","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep41619-bib-0013-20241015","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High\u2010dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"50","year":"2009","journal-title":"Hepatology"},{"key":"hep41619-bib-0014-20241015","doi-asserted-by":"crossref","first-page":"478","DOI":"10.2174\/187152812803589976","article-title":"Innate immunity in the pathogenesis of cholangiopathy: a recent update","volume":"11","year":"2012","journal-title":"Inflamm Allergy Drug Targets"},{"key":"hep41619-bib-0015-20241015","first-page":"66","article-title":"Expression of monocyte chemotactic protein\u20101 precedes monocyte recruitment in a rat model of acute liver injury, and is modulated by vitamin E","volume":"47","year":"1999","journal-title":"J Investig Med"},{"key":"hep41619-bib-0016-20241015","doi-asserted-by":"crossref","first-page":"G1310","DOI":"10.1152\/ajpgi.00365.2011","article-title":"Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2","volume":"302","year":"2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"hep41619-bib-0017-20241015","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/hep.26993","article-title":"Cholangiocyte senescence by way of N\u2010ras activation is a characteristic of primary sclerosing cholangitis","volume":"59","year":"2014","journal-title":"Hepatology"},{"key":"hep41619-bib-0018-20241015","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1080\/00365520701320521","article-title":"Multiple inflammatory\u2010, tissue remodelling\u2010 and fibrosis genes are differentially transcribed in the livers of Abcb4 (\u2010\/\u2010) mice harbouring chronic cholangitis","volume":"42","year":"2007","journal-title":"Scand J Gastroenterol"},{"key":"hep41619-bib-0019-20241015","article-title":"Antifibrotic effects of the dual CCR2\/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis","volume":"11","year":"2016","journal-title":"PLoS One"},{"key":"hep41619-bib-0020-20241015","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/hep.28682","article-title":"Chemokine (C\u2010C motif) receptor 2\u2010positive monocytes aggravate the early phase of acetaminophen\u2010induced acute liver injury","volume":"64","year":"2016","journal-title":"Hepatology"},{"key":"hep41619-bib-0021-20241015","article-title":"Differential impact of the dual CCR2\/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury","volume":"12","year":"2017","journal-title":"PLoS One"},{"key":"hep41619-bib-0022-20241015","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/liv.13698","article-title":"Cenicriviroc, a cytokine receptor antagonist, potentiates all\u2010trans retinoic acid in reducing liver injury in cholestatic rodents","volume":"38","year":"2018","journal-title":"Liver Int"},{"key":"hep41619-bib-0023-20241015","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/hep.29544","article-title":"Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis","volume":"67","year":"2018","journal-title":"Hepatology"},{"key":"hep41619-bib-0024-20241015","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jhep.2018.05.018","article-title":"Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"hep41619-bib-0025-20241015","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A randomized, placebo\u2010controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","year":"2018","journal-title":"Hepatology"},{"key":"hep41619-bib-0026-20241015","first-page":"213","article-title":"The role of chemokines in acute liver injury","volume":"3","year":"2012","journal-title":"Front Physiol"},{"key":"hep41619-bib-0027-20241015","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2174\/187152811798104890","article-title":"Modification of chemokine pathways and immune cell infiltration as a novel therapeutic approach in liver inflammation and fibrosis","volume":"10","year":"2011","journal-title":"Inflamm Allergy Drug Targets"},{"key":"hep41619-bib-0028-20241015","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/hep.22952","article-title":"CCR2 promotes hepatic fibrosis in mice","volume":"50","year":"2009","journal-title":"Hepatology"},{"key":"hep41619-bib-0029-20241015","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.28256","article-title":"Surrogate endpoints for clinical trials in primary sclerosing cholangitis: review and results from an International PSC Study Group consensus process","volume":"63","year":"2016","journal-title":"Hepatology"},{"key":"hep41619-bib-0030-20241015","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/hep.29882","article-title":"Design and endpoints for clinical trials in primary sclerosing cholangitis","volume":"68","year":"2018","journal-title":"Hepatology"},{"key":"hep41619-bib-0031-20241015","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/liv.12894","article-title":"Risk factors for primary sclerosing cholangitis","volume":"36","year":"2016","journal-title":"Liver Int"},{"key":"hep41619-bib-0032-20241015","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/0016-5085(88)90378-2","article-title":"Primary sclerosing cholangitis with normal serum alkaline phosphatase activity","volume":"95","year":"1988","journal-title":"Gastroenterology"},{"key":"hep41619-bib-0033-20241015","first-page":"136","article-title":"Spontaneous course of symptoms in primary sclerosing cholangitis: relationships with biochemical and histological features","volume":"46","year":"1999","journal-title":"Hepatogastroenterology"},{"key":"hep41619-bib-0034-20241015","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1053\/j.gastro.2005.08.017","article-title":"High\u2010dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5\u2010year multicenter, randomized, controlled study","volume":"129","year":"2005","journal-title":"Gastroenterology"},{"key":"hep41619-bib-0035-20241015","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.dld.2010.12.008","article-title":"Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis","volume":"43","year":"2011","journal-title":"Dig Liver Dis"},{"key":"hep41619-bib-0036-20241015","doi-asserted-by":"crossref","first-page":"6843","DOI":"10.4049\/jimmunol.0903987","article-title":"An independent subset of TLR expressing CCR2\u2010dependent macrophages promotes colonic inflammation","volume":"184","year":"2010","journal-title":"J Immunol"},{"key":"hep41619-bib-0037-20241015","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/00365521.2017.1281435","article-title":"CCR5 expression in inflammatory bowel disease and its correlation with inflammatory cells and \u03b2\u2010arrestin2 expression","volume":"52","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"hep41619-bib-0038-20241015","article-title":"The AESOP trial: a randomized, double\u2010blind, placebo\u2010controlled, phase 2 study of obeticholic acid in patients with primary sclerosing cholangitis","volume":"66","year":"2017","journal-title":"Hepatology"},{"key":"hep41619-bib-0039-20241015","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/QAD.0000000000000988","article-title":"A 48\u2010week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment\u2010naive HIV\u2010infected adults with C\u2010C chemokine receptor type 5\u2010tropic virus","volume":"30","year":"2016","journal-title":"AIDS"},{"key":"hep41619-bib-0040-20241015","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1111\/liv.13402","article-title":"Enhanced liver fibrosis test predicts transplant\u2010free survival in primary sclerosing cholangitis, a multi\u2010centre study","volume":"37","year":"2017","journal-title":"Liver Int"},{"key":"hep41619-bib-0041-20241015","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jhep.2017.01.019","article-title":"Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"hep41619-bib-0042-20241015","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/hep.27825","article-title":"Enhanced liver fibrosis score predicts transplant\u2010free survival in primary sclerosing cholangitis","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"hep41619-bib-0043-20241015","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/liv.12700","article-title":"Plasma Pro\u2010C3 (N\u2010terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C","volume":"35","year":"2015","journal-title":"Liver Int"},{"key":"hep41619-bib-0046-20241015","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"hep41619-bib-0047-20241015","article-title":"NGM282, an engineered analogue of FGF19, significantly improves markers of bile acid synthesis, hepatic injury and fibrosis in PSC patients: results of a phase 2, multicenter, randomized, double\u2010blind, placebo\u2010controlled trial","volume":"68","year":"2018","journal-title":"J Hepatol"}],"container-title":["Hepatology Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep4.1619","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep4.1619","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.1619","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T18:15:34Z","timestamp":1729016134000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.1619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,22]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1002\/hep4.1619","relation":{},"ISSN":["2471-254X","2471-254X"],"issn-type":[{"value":"2471-254X","type":"print"},{"value":"2471-254X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,22]]},"assertion":[{"value":"2019-12-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}